Related Experiment Video
Updated: May 28, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Treating tumors with a vaccinia virus expressing IFNβ illustrates the complex relationships between oncolytic ability
Liang-Chuan S Wang1, Rachel C Lynn, Guanjun Cheng
1Division of Pulmonary, Thoracic Oncology Research Laboratory, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA.
Abstract:
Since previous work using a nonreplicating adenovirus-expressing mouse interferon-β (Ad.mIFNβ) showed promising preclinical activity, we postulated that a vector-expressing IFNβ at high levels that could also replicate would be even more beneficial. Accordingly a replication competent, recombinant vaccinia viral vector-expressing mIFNβ (VV.mIFNβ) was tested. VV.mIFNβ-induced antitumor responses in two syngeneic mouse flank models of lung cancer. Although VV.mIFNβ had equivalent in vivo efficacy in both murine tumor models, the mechanisms of tumor killing were completely different. In LKRM2 tumors, viral replication was minimal and the tumor killing mechanism was due to activation of immune responses through induction of a local inflammatory response and production of antitumor CD8 T-cells. In contrast, in TC-1 tumors, the vector replicated well, induced an innate immune response, but antitumor activity was primarily due to a direct oncolytic effect. However, the VV.mIFNβ vector was able to augment the efficacy of an antitumor vaccine in the TC-1 tumor model in association with increased numbers of infiltrating CD8 T-cells. These data show the complex relationships between oncolytic viruses and the immune system which, if understood and harnessed correctly, could potentially be used to enhance the efficacy of immunotherapy.
Insights
A novel vaccinia virus expressing mouse interferon-beta (VV.mIFNβ) showed antitumor effects in lung cancer models. Mechanisms varied, involving immune activation or direct oncolysis, highlighting virus-immune interactions for immunotherapy enhancement.
Area of Science:
- Oncolytic virotherapy
- Immunotherapy
- Cancer research
Background:
- Previous studies utilized nonreplicating adenovirus expressing mouse interferon-beta (Ad.mIFNβ) with promising preclinical activity.
- A replication-competent vector expressing interferon-beta at high levels was hypothesized to be more beneficial.
Purpose of the Study:
- To evaluate a recombinant vaccinia viral vector expressing mouse interferon-beta (VV.mIFNβ) for its antitumor efficacy.
- To investigate the distinct mechanisms of tumor killing induced by VV.mIFNβ in different murine lung cancer models.
Main Methods:
- Development and testing of a replication-competent vaccinia viral vector expressing mouse interferon-beta (VV.mIFNβ).
- Assessment of in vivo antitumor responses in two syngeneic mouse flank models of lung cancer (LKRM2 and TC-1).
- Analysis of viral replication, immune response induction (innate and adaptive, including CD8 T-cells), and direct oncolytic effects.
Main Results:
- VV.mIFNβ demonstrated antitumor activity in both LKRM2 and TC-1 lung cancer models with equivalent efficacy.
- In LKRM2 tumors, minimal viral replication occurred, with tumor killing driven by immune activation and CD8 T-cell production.
- In TC-1 tumors, significant viral replication led to direct oncolysis, with VV.mIFNβ also augmenting antitumor vaccine efficacy by increasing CD8 T-cell infiltration.
Conclusions:
- VV.mIFNβ exhibits potent antitumor activity through distinct mechanisms dependent on the tumor microenvironment.
- The study underscores the complex interplay between oncolytic viruses and the immune system.
- Understanding these interactions is crucial for harnessing oncolytic viruses to enhance cancer immunotherapy efficacy.
Related Concept Videos
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immune Response Against Viral Pathogens
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
Mechanisms of Retrovirus-induced Cancers
Mechanisms of Retrovirus-induced Cancers

